Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P {6-11}
โ Scribed by J.D. Jonkman-de Vries; H. Rosing; H. Talsma; R.E.C. Henrar; J.J. Kettenes-van den Bosch; A. Bult; J.H. Beijnen
- Book ID
- 110231562
- Publisher
- Springer US
- Year
- 1998
- Tongue
- English
- Weight
- 113 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0167-6997
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Antagonist \(\left[\mathrm{Arg}^{6}\right.\), D-Trp \({ }^{7,9}\), MePhe \(\left.^{8}\right]\)-substance P \{611) was subjected to a systematic stability study in which kinetic parameters were obtained for the degradation of this hexapeptide under several well-defined conditions. The influences of \
Reversed-phase high-performance liquid chromatography and capillary zone electrophoresis are widely used in protein and peptide analysis. Degradation of the basic peptide \(\left[\right.\) Arg \(^{6}\), D-Trp \({ }^{7,9}\), MePhe \(\left.^{8}\right]\)-substance P \(\{6-\) 11 (antagonist G) was monit